ALLMedicine™ Acute Promyelocytic Leukemia Center
Research & Reviews 1,133 results
https://doi.org/10.1007/s00280-022-04449-9 10.1002/ajh.25271 10.1200/JCO.2013.48.8312 10.1073/pnas.0712365105 10.3760/j.issn:0578-1310.2005.09.020 10.1002/pbc.22042 10.7534/j.issn.1009-2137.2017.06.004 10.3760/cma.j.issn.0578-1310.2019.10.006 10.1182/blood.V89.9.3345 10.1080/17512433.2021.1893940 10.1016/j.jpba.2019.04.014 10.1016/j.leukres.2017.09.006 10.1200/JCO.20.03096 10.2147/DDDT.S305244 10.3760/cma.j.issn.0253-2727.2009.07.004 10.3760/j.issn:0578-1426.2005.10.005 10.1289/ehp.1510412 10.1007/s00280-018-3606-8 10.1124/jpet.108.139543
Cancer Chemotherapy and Pharmacology; Liao LH, Chen YQ et. al.
Jun 28th, 2022 - Realgar-Indigo naturalis formula (RIF) is a traditional Chinese medicine containing As4S4 and effective in treating acute promyelocytic leukemia (APL). The dose of RIF remains to be determined in pediatric patients. Comparison of plasma arsenic co...
https://doi.org/10.1080/10428194.2022.2090554
Leukemia & Lymphoma; Dhakal P, Joshi U et. al.
Jun 24th, 2022 - Understanding the association between insurance status and survival in an evolving US healthcare system remains a challenge but is essential to address healthcare disparities. We utilized National Cancer Database to evaluate the effects of insuran...
https://doi.org/10.1002/cyto.b.22085
Cytometry. Part B, Clinical Cytometry; Fang H, Wang SA et. al.
Jun 19th, 2022 - Prompt diagnosis of acute promyelocytic leukemia (APL) is critical for patient care. In this study, we aimed to characterize the immunophenotype of APL and explore immunophenotypic difference between APL and its mimics using flow cytometric analys...
https://doi.org/10.1186/s12879-022-07513-0 10.1056/NEJMoa2001017 10.1038/s41564-020-00789-5 10.1126/science.abb8925 10.1126/science.1185181 10.1056/NEJMoa1800820 10.1038/s41467-020-19568-1 10.1056/NEJMoa2035002 10.1126/science.abd0827 10.1038/s41577-021-00542-x 10.1056/NEJM199307153290307 10.1111/bjh.16151 10.1056/NEJMra2026131 10.1016/S2666-5247(20)30144-0 10.1038/s41577-020-0311-8 10.7326/0003-4819-117-4-292 10.1186/s12885-020-6533-0 10.1038/nrc2943 10.1016/0002-9343(91)90069-A 10.1016/S0140-6736(20)30211-7
BMC Infectious Diseases; Hegazy AN, Krönke J et. al.
Jun 13th, 2022 - Passive immunization against SARS-CoV-2 limits viral burden and death from COVID-19; however, it poses a theoretical risk of disease exacerbation through antibody-dependent enhancement (ADE). ADE after anti-SARS-CoV2 antibody treatment has not bee...
https://doi.org/10.1182/blood.2021014945
Blood Song H, Liu Y et. al.
Jun 3rd, 2022 - Genetic alternations can occur at non-coding regions, but how they contribute to cancer pathogenesis is poorly understood. Here we established a mutational landscape of cis-regulatory regions (CREs) in acute promyelocytic leukemia (APL) based on w...
Guidelines 2 results
https://doi.org/10.6004/jnccn.2021.0002
Journal of the National Comprehensive Cancer Network : JN... Pollyea DA, Bixby D et. al.
Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161234
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.
Sep 14th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...
Drugs 14 results see all →
Clinicaltrials.gov 82 results
https://clinicaltrials.gov/ct2/show/NCT01409161
May 10th, 2022 - PRIMARY OBJECTIVES: I. Assess whether a combination of all-trans retinoic acid (ATRA [tretinoin]), and arsenic trioxide (ATO) can produce long-term event-free survival in patients with low-risk untreated acute promyelocytic leukemia (APL). II. Ass...
https://clinicaltrials.gov/ct2/show/NCT02200978
May 10th, 2022 - OBJECTIVES: Determine the safety and efficacy of "ATO/RIF + ATRA + less intensive chemotherapy" protocol in children with acute promyelocytic leukemia (APL). Compare the safety，efficacy and treatment cost of "RIF + ATRA + less intensive chemother...
https://clinicaltrials.gov/ct2/show/NCT01518556
Apr 15th, 2022 - Up to nowadays, a standard induction therapy for acute myeloid leukemia(AML) has consisted of cytarabine 100-200 mg per square meter of body surface area(BSA) per day continuous infusion for 7 days with idarubicin 12 mg per square meter or daunoru...
https://clinicaltrials.gov/ct2/show/NCT05297123
Mar 28th, 2022 - Acute myeloid leukemia (AML) is a genetically heterogeneous disease with a highly variable prognosis and an overall high mortality rate. The 5-year overall survival of adult AML patients is less than 50%, and only 20% of elderly patients survive o...
https://clinicaltrials.gov/ct2/show/NCT00866918
Mar 25th, 2022 - PRIMARY OBJECTIVES: I. To decrease the total anthracycline dose from the best current published results in standard risk childhood acute promyelocytic leukemia (APL) while still maintaining a comparable event-free survival (EFS). SECONDARY OBJECTI...
News 100 results
https://www.onclive.com/view/fda-grants-fast-track-status-to-prgn-3006-for-relapsed-refractory-aml
May 2nd, 2022 - The FDA has granted a fast track designation to the multigenic autologous CAR T-cell therapy PRGN-3006 for use as a potential therapeutic option in patients with relapsed or refractory acute myeloid leukemia (AML), according to an announcement fro...
https://www.medscape.com/viewarticle/964529
Apr 14th, 2022 - This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz, and welcome to Medscape InDiscussion. Today, we're going to be talking about acute myeloid leukemia (AML) and specifically a subtype of AML, ca...
https://www.medscape.com/viewarticle/964531
Apr 14th, 2022 - This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and the NewYork-Presbyterian Hospital in New York Ci...
https://www.mdedge.com/hematology-oncology/article/249816/aml
Caleb Rans, PharmD
Dec 12th, 2021 - The emergence of precision medicine has ushered in a groundbreaking era for the treatment of myeloid malignancies, with the ability to integrate individual molecular data into patient care. Over the past decade, insights from research focusing on.
https://www.medscape.com/viewarticle/964213
Dec 6th, 2021 - A drug crucial for the emergency management of acute promyelocytic leukemia (APL) simply isn't stocked by many US hospitals, according to a recent report in the Journal of the National Comprehensive Cancer Network. The drug — all-trans retinoic ac...
